ASCENTAGE PHARMA GROUP INTERNATIONAL

Corporate Details

ISIN(s):

US04390B1052

LEI:

Country:

United States of America

Address:

68 XINQING ROAD, 0 SUZHOU , JIANGSU

Website:

https://www.ascentage.cn/

Sector:

Manufacturing

Industry:

Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ascentage Pharma Group International is a global, clinical-stage biopharmaceutical company focused on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases with unmet medical needs. The company's core R&D strategy targets apoptosis pathways, specializing in small-molecule drug candidates that inhibit protein-protein interactions. Its robust pipeline features potential first-in-class and best-in-class assets, including the approved third-generation BCR-ABL inhibitor olverembatinib and the Bcl-2 inhibitor lisaftoclax. With over 40 clinical trials active globally, Ascentage Pharma has secured numerous priority and orphan drug designations from the US FDA and China's CDE. The company actively pursues a global strategy through clinical and commercial collaborations with leading pharmaceutical companies and research institutions.